Startup

VectorY Therapeutics

Amsterdam biotech developing AAV-delivered vectorized antibodies for ALS and other neurodegenerative diseases

  • Biotech & Life Sciences
  • Amsterdam, The Netherlands
  • Series A

About VectorY Therapeutics

VectorY Therapeutics is an Amsterdam-based biotech company developing vectorized antibody therapies for neurodegenerative diseases. Its approach uses AAV gene therapy to make neurons produce therapeutic antibodies themselves. The lead program, VTx-002, targets TDP-43 pathology in ALS and is in the Phase 1/2 PIONEER-ALS trial, which dosed its first participant in February 2026. A second program, VTx-003, targets Huntington's disease.

Founders

  • Jim Scibetta

    CEO (since Dec 2024, not a founder)

  • Sander van Deventer

    Co-founder, President of R&D (CEO Nov 2022 - Dec 2024)

    Co-founder of VectorY, Amsterdam Molecular Therapeutics (now uniQure) and Forbion; involved in developing Remicade and Glybera.

VectorY Therapeutics logo
Industry
Biotech & Life Sciences
Based in
Amsterdam, The Netherlands
Stage
Series A

Funding rounds

DateRoundAmountLead investors
Series A€74.5mNew: Angelini Ventures, Invest-NL, European Investment Bank; returning: Forbion, EQT Life Sciences, Eli Lilly and others
Series A€129.0mEQT Life Sciences, Forbion